Module 10: Somatic Interpretation Frameworks: AMP/ASCO/CAP Tiers & ClinGen Criteria
1. The AMP/ASCO/CAP 2017 Somatic Variant Classification System
Unlike germline variants—which are classified under ACMG/AMP 2015 5-tier guidelines into Pathogenic, Likely Pathogenic, VUS, Likely Benign, and Benign based on disease causality—somatic cancer alterations must be classified by their clinical actionability and therapeutic utility. In 2017, the Association for Molecular Pathology (AMP), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP) established the definitive 4-tier clinical oncology framework:
| Clinical Tier | Clinical Significance | Evidence Levels Included | Actionability & Reporting Mandate |
|---|---|---|---|
| Tier I | Variants of Strong Clinical Significance | Level A: FDA-approved therapies or inclusion in professional guidelines (NCCN) for specific tumor type. Level B: Well-powered clinical studies with consensus in specific tumor type. | High Actionability: Must be reported prominently at top of clinical report; directs standard-of-care therapy. |
| Tier II | Variants of Potential Clinical Significance | Level C: FDA-approved therapy in different tumor type (off-label) or inclusion in clinical trials. Level D: Preclinical biomarker (in vitro / in vivo) or investigational clinical trials. | Potential Actionability: Eligible for off-label expanded access or enrollment in targeted clinical trials. |
| Tier III | Variants of Uncertain Clinical Significance (VUS) | Insufficient biological evidence; unknown therapeutic, prognostic, or diagnostic consequence. | Reported separately; must not be used for therapeutic decisions without further trial evidence. |
| Tier IV | Benign or Likely Benign Variants | Observed at high frequency ($ ext{AF} > 1\%$) in gnomAD; no oncogenic transforming potential. | Do not report in diagnostic clinical reports. |
2. ClinGen / CGC / VICC Oncogenicity Criteria
To standardize whether a mutation is truly oncogenic (biochemically transforming) independent of current drug approvals, the Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC) developed oncogenicity rules analogous to ACMG criteria:
- OS1 (Very Strong): Same amino acid change previously established as an oncogenic driver in peer-reviewed clinical cohorts.
- OS2 (Strong): Well-characterized functional assays demonstrate transforming capacity, factor independence, or constitutive catalytic activation.
- OS3 (Moderate): Located within a recognized mutational hotspot or critical catalytic functional domain (e.g. kinase loop).
- OP1 (Supporting): Absence from broad population reference databases (gnomAD AF $pprox 0$).
3. VUS Management & Tumor-Only Caveats
Clinicians must be cautioned against treating VUSs with off-label targeted drugs. Treating a patient with an unvalidated VUS in EGFR with costly TKIs exposes the patient to unnecessary toxicities without proven efficacy. When an incidental putative germline variant is detected in tumor-only sequencing (e.g. BRCA1 stop-gain with 48% VAF), the report must formally recommend orthogonal germline confirmation by clinical genetics.
Common Pitfalls & Troubleshooting Checklist
- Java Heap Exhaustion (GATK / Picard): If processes terminate with
java.lang.OutOfMemoryError, set your environment variable explicitly:export _JAVA_OPTIONS="-Xmx16g -Djava.io.tmpdir=/tmp". - Index Timestamp Mismatch: If tools complain that a BAM index is missing or out of date, regenerate with
samtools index -@ 4 sample.bam. - Conda Channel Conflicts: Avoid ABI incompatibilities between bioconda and conda-forge by setting strict priority:
conda config --set channel_priority strict. - Chromosome Naming Contamination: Always verify whether reference FASTA headers use
chr1or1; divergent naming causes silent alignment drops.